Cargando…

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial

BACKGROUND: The prognostic interrelationship between natriuretic peptide (NP) levels and body mass index (BMI) among patients with chronic stable heart failure with preserved ejection fraction is not well characterized. METHODS AND RESULTS: Participants from the TOPCAT (Treatment of Preserved Cardia...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Ambarish, Berry, Jarett D., Drazner, Mark H., Fang, James C, Tang, W. H. Wilson, Grodin, Justin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404179/
https://www.ncbi.nlm.nih.gov/pubmed/30376747
http://dx.doi.org/10.1161/JAHA.118.009664
_version_ 1783400817289592832
author Pandey, Ambarish
Berry, Jarett D.
Drazner, Mark H.
Fang, James C
Tang, W. H. Wilson
Grodin, Justin L.
author_facet Pandey, Ambarish
Berry, Jarett D.
Drazner, Mark H.
Fang, James C
Tang, W. H. Wilson
Grodin, Justin L.
author_sort Pandey, Ambarish
collection PubMed
description BACKGROUND: The prognostic interrelationship between natriuretic peptide (NP) levels and body mass index (BMI) among patients with chronic stable heart failure with preserved ejection fraction is not well characterized. METHODS AND RESULTS: Participants from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial enrolled in the Americas meeting inclusion by the NP stratum were stratified into 4 data‐derived categories by BMI and standardized NP‐z score. Adjusted Cox‐proportional models determined the independent association of BMI, NP‐z score, and BMI/NP categories with composite primary end point, heart failure hospitalization, and all‐cause mortality. The study population included 997 participants. There was a U‐shaped relationship between BMI and NP with elevated NP levels noted at extremes of BMI distribution. There was also a U‐shaped relationship between BMI and risk of adverse clinical outcomes with the lowest risk among patients approximating a BMI of 25 kg/m(2). In contrast, higher NP levels were linearly associated with higher risk of adverse clinical outcomes. For BMI/NP‐based categories, participants in the high BMI/high NP group had greater prevalence of cardiac structural and functional abnormalities and the highest risk of adverse clinical outcomes (hazard ratio for primary end point; 95% confidence interval: 2.29 [1.36–3.84] Reference: low BMI/low NP). CONCLUSIONS: There is a U‐shaped association between BMI and NP levels among patients with chronic heart failure with preserved ejection fraction. Higher NP levels are independently associated with a higher risk of mortality across both high and low BMI strata. Among obese patients with heart failure with preserved ejection fraction, elevated NP levels identify a higher risk phenotype with a significantly increased incidence of both mortality and heart failure hospitalization.
format Online
Article
Text
id pubmed-6404179
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64041792019-03-18 Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial Pandey, Ambarish Berry, Jarett D. Drazner, Mark H. Fang, James C Tang, W. H. Wilson Grodin, Justin L. J Am Heart Assoc Original Research BACKGROUND: The prognostic interrelationship between natriuretic peptide (NP) levels and body mass index (BMI) among patients with chronic stable heart failure with preserved ejection fraction is not well characterized. METHODS AND RESULTS: Participants from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial enrolled in the Americas meeting inclusion by the NP stratum were stratified into 4 data‐derived categories by BMI and standardized NP‐z score. Adjusted Cox‐proportional models determined the independent association of BMI, NP‐z score, and BMI/NP categories with composite primary end point, heart failure hospitalization, and all‐cause mortality. The study population included 997 participants. There was a U‐shaped relationship between BMI and NP with elevated NP levels noted at extremes of BMI distribution. There was also a U‐shaped relationship between BMI and risk of adverse clinical outcomes with the lowest risk among patients approximating a BMI of 25 kg/m(2). In contrast, higher NP levels were linearly associated with higher risk of adverse clinical outcomes. For BMI/NP‐based categories, participants in the high BMI/high NP group had greater prevalence of cardiac structural and functional abnormalities and the highest risk of adverse clinical outcomes (hazard ratio for primary end point; 95% confidence interval: 2.29 [1.36–3.84] Reference: low BMI/low NP). CONCLUSIONS: There is a U‐shaped association between BMI and NP levels among patients with chronic heart failure with preserved ejection fraction. Higher NP levels are independently associated with a higher risk of mortality across both high and low BMI strata. Among obese patients with heart failure with preserved ejection fraction, elevated NP levels identify a higher risk phenotype with a significantly increased incidence of both mortality and heart failure hospitalization. John Wiley and Sons Inc. 2018-10-31 /pmc/articles/PMC6404179/ /pubmed/30376747 http://dx.doi.org/10.1161/JAHA.118.009664 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Pandey, Ambarish
Berry, Jarett D.
Drazner, Mark H.
Fang, James C
Tang, W. H. Wilson
Grodin, Justin L.
Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
title Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
title_full Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
title_fullStr Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
title_full_unstemmed Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
title_short Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
title_sort body mass index, natriuretic peptides, and risk of adverse outcomes in patients with heart failure and preserved ejection fraction: analysis from the topcat trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404179/
https://www.ncbi.nlm.nih.gov/pubmed/30376747
http://dx.doi.org/10.1161/JAHA.118.009664
work_keys_str_mv AT pandeyambarish bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial
AT berryjarettd bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial
AT draznermarkh bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial
AT fangjamesc bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial
AT tangwhwilson bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial
AT grodinjustinl bodymassindexnatriureticpeptidesandriskofadverseoutcomesinpatientswithheartfailureandpreservedejectionfractionanalysisfromthetopcattrial